However, no significant difference was detected when comparing SPG7 variant carriers with clinical or radiological signs of FTD (4/9: 44%) and non-SPG7 variant carriers exhibiting cognitive impairment consistent with FTD as assessed by ECAS (9/30: 30%; P = 0.337, two-sided Fisher’s exact test). This evidence concerns the gene SPG7 and Cognitive impairment.